Back to Latest FDA Approvals
Boniva IV Injection
Generic Name: ibandronate sodium
Date of Approval: January 6, 2006
Company: Roche/GlaxoSmithKline
Treatment for: Postmenopausal Osteoporosis
FDA has approves Boniva Injection
The U.S. Food and Drug Administration (FDA) has approved Boniva (ibandronate sodium) Injection, the first intravenous (IV) medication for the treatment of postmenopausal osteoporosis.
What is Boniva IV?
Boniva Injection, the first quarterly medication for the treatment of postmenopausal osteoporosis, is a member of the bisphosphonate class, which is the most frequently prescribed medicine for osteoporosis.1 It is administered by a healthcare professional once every three months.
